Lactobionic acid reduces body weight gain in diet-induced obese rats by targeted inhibition of galectin-1

Mukherjee, Rajib; Yun, Jong Won

doi:10.1016/j.bbrc.2015.06.114

Cited by 20 publications

(18 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BMI, waist, insulin and triglycerides had a stronger correlation with galectin-1 than markers of glycemia such as glucose and HbA1c. In line with the observed associations, recent animal studies have indicated a role for galectin-1 in obesity [ 2 , [8] , [9] , [10] ]. In rats, treatment with the galectin-1 inhibitor thiodigalactoside induced weight loss and suppressed triglyceride synthesis and lipid storage, suggesting that the inhibitor interferes with lipid droplet formation [ 8 ].…”

Section: Discussionsupporting

confidence: 64%

Galectin-1 is inversely associated with type 2 diabetes independently of obesity – A SCAPIS pilot study

et al. 2019

View full text Add to dashboard Cite

Objectives Galectin-1 is a recently discovered adipokine that increases with obesity and increased energy intake in adipose tissue. Our aim was to assess whether serum galectin-1 is associated with type 2 diabetes (T2D) and other parameters of the metabolic syndrome independently of body mass index (BMI) in a cohort from the general population. Methods In this cross-sectional population-based cohort study from the western part of Sweden, we investigated associations between serum galectin-1, clinical characteristics and inflammatory markers in 989 women and men aged 50–65 years [part of the Swedish CArdioPulmonary bioImage Study (SCAPIS) pilot cohort]. Results We showed in linear models that serum galectin-1 was independently and: (1) inversely associated with T2D (p < 0.05) and glucose (p < 0.05); and (2) positively associated with age (p < 0.01), sex (p < 0.01), BMI (p < 0.01), insulin (p < 0.01) and C-reactive protein (p < 0.01). Furthermore, galectin-1 demonstrated univariate correlations with triglycerides (r = 0.20, p < 0.01), homeostasis model assessment for insulin resistance (r = 0.24, p < 0.01), tumor necrosis factor-α (r = 0.24, p < 0.01), interleukin-6 (IL-6; r = 0.20, p < 0.01) and HbA1c (r = 0.14, p < 0.01). Conclusion In a cross-sectional study of a middle-aged population, we showed that serum galectin-1 is: (1) inversely associated with T2D independently of BMI; and (2) independently associated with other markers of the metabolic syndrome These results warrant prospective and functional studies on the role of galectin-1 in T2D.

show abstract

Section: Discussionsupporting

confidence: 64%

Galectin-1 is inversely associated with type 2 diabetes independently of obesity – A SCAPIS pilot study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…LBA seems to be resistant to digestive enzymes, so it reaches the colon intact, where it is fermented by microbiota [80], probably interfering with lactose absorption, which may cause a binding competition [79,81]. On the other hand, LBA also has anti-inflammatory properties, and in a study on mice, it was demonstrated that its administration is associated with a decrease of obesity and a better control of metabolic parameters [82].…”

Section: New Molecules With Prebiotic Effectsmentioning

confidence: 99%

“…↑ Lactobacilli and Bifidobacterium growth [79]. Has anti-inflammatory properties, ↓ obesity and improves metabolic parameters [82].…”

Section: Lactobionic Acidmentioning

confidence: 99%

Mechanisms of Action of Prebiotics and Their Effects on Gastro-Intestinal Disorders in Adults

et al. 2020

View full text Add to dashboard Cite

In recent years, research has focused on the use of dietary fibers and prebiotics, since many of these polysaccharides can be metabolized by intestinal microbiota, leading to the production of short-chain fatty acids. The metabolites of prebiotic fermentation also show anti-inflammatory and immunomodulatory capabilities, suggesting an interesting role in the treatment of several pathological conditions. Galacto-oligosaccharide and short-and long-chain fructans (Fructo-oligosaccharides and inulin) are the most studied prebiotics, even if other dietary compounds seem to show the same features. There is an increasing interest in dietary strategies to modulate microbiota. The aim of this review is to explore the mechanisms of action of prebiotics and their effects on the principal gastro-intestinal disorders in adults, with a special focus on Galacto-oligosaccharides, Fructo-oligosaccharides, lactulose and new emerging substances which currently have evidence of prebiotics effects, such as xilooligosaccharides, soybean oligosaccharides, isomaltooligosaccharides, lactobionic acid, resistant starch and polyphenols.

show abstract

“…Mukherjee and Yun () performed an in vivo (rats) investigation of LBA for its antiobesity efficiency, where a significant reduction in the lipogenic capacity for both oral administration and intraperitoneal injection of the acid. There was substantial reduction of the body weight gain and improvement in metabolic parameters, which makes it a potential antiobesity compound.…”

Section: Effects Of Lba In Humansmentioning

confidence: 99%

“…Moreover, it can be also considered an efficient therapeutic compound due to high affinity with endocytotic receptor that overexpresses on human hepatic carcinoma, nowadays highly used as antirejection agent, with medical purposes (Wei et al, 2017). Mukherjee and Yun (2015) performed an in vivo (rats) investigation of LBA for its antiobesity efficiency, where a significant reduction in the lipogenic capacity for both oral administration and intraperitoneal injection of the acid. There was substantial reduction of the body weight gain and improvement in metabolic parameters, which makes it a potential antiobesity compound.…”

Section: Effects Of Lba In Humansmentioning

confidence: 99%

Lactobionic Acid as a Potential Food Ingredient: Recent Studies and Applications

Cardoso

Marques

Dagostin

et al. 2019

Journal of Food Science

View full text Add to dashboard Cite

Lactobionic acid (LBA) is a bionic acid naturally found in the “Caspian Sea yogurt” and chemically constituted of a gluconic acid bonded to a galactose. The compound is known for its numerous proven attributes as an antioxidant, chelator, and moisturizer agent. There is a growing interest of the academic community and industry research sectors in the application of LBA as a food ingredient. Thus, this review describes the current methods of LBA production, patents related, general applications and regulations, research statistics, future prospects, and an overview of the challenges faced by the food industry to incorporate the acid in their products. Studies associated to food application and human intake are scarce in the literature. To date, they account for only a small amount of all available research papers and patents on the subject, which is due to LBA prohibitions despite the approval of its salt (calcium lactobionate) and the lack of regulation in most countries. Further studies on the safety of consumption should be carried out in coming years in order to elucidate its toxicological aspects and to extend the technological possibilities of the food processing industry.

show abstract

Lactobionic acid reduces body weight gain in diet-induced obese rats by targeted inhibition of galectin-1

Cited by 20 publications

References 34 publications

Galectin-1 is inversely associated with type 2 diabetes independently of obesity – A SCAPIS pilot study

Galectin-1 is inversely associated with type 2 diabetes independently of obesity – A SCAPIS pilot study

Mechanisms of Action of Prebiotics and Their Effects on Gastro-Intestinal Disorders in Adults

Lactobionic Acid as a Potential Food Ingredient: Recent Studies and Applications

Contact Info

Product

Resources

About